PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32924987-8 2021 Gene set variation analysis (GSVA) showed that activity in the cell cycle/mitotic, ERBB, and ERK/MAPK pathways was higher in the high-risk compared with the low-risk group, which may lead to differences in OS.Interestingly, we observed that patients in the high-risk group were more sensitive to gemcitabine and docetaxel than the low-risk group, which is consistent with results of the GSVA. Docetaxel 312-321 mitogen-activated protein kinase 1 Homo sapiens 93-96 26546439-12 2016 FLNA can function as a modulator of chemosensitivity to docetaxel in TNBC cells through regulation of the MAPK/ERK pathway both in vitro and in vivo. Docetaxel 56-65 mitogen-activated protein kinase 1 Homo sapiens 111-114 32179814-7 2020 Besides, melatonin prevented the positive actions that docetaxel exerts on the expression of other factors related to angiogenesis like JAG1, ANPEP, IGF-1, CXCL6, AKT1, ERK1, ERK2, MMP14 and NOS3 and neutralized the stimulating actions of vinorelbine on the expression of FIGF, FGFR3, CXCL6, CCL2, ERK1, ERK2, AKT1, NOS3 and MMP14. Docetaxel 55-64 mitogen-activated protein kinase 1 Homo sapiens 175-179 32179814-7 2020 Besides, melatonin prevented the positive actions that docetaxel exerts on the expression of other factors related to angiogenesis like JAG1, ANPEP, IGF-1, CXCL6, AKT1, ERK1, ERK2, MMP14 and NOS3 and neutralized the stimulating actions of vinorelbine on the expression of FIGF, FGFR3, CXCL6, CCL2, ERK1, ERK2, AKT1, NOS3 and MMP14. Docetaxel 55-64 mitogen-activated protein kinase 1 Homo sapiens 304-308 26821209-0 2016 Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCepsilon/delta-induced ERK pathways. Docetaxel 68-77 mitogen-activated protein kinase 1 Homo sapiens 153-156 29373811-7 2019 In summary, CASC2 competes with SPRY2 for miR-183 binding to rescue the expression of SPRY2 in PC cells, thus enhancing the sensitivity of PC cells to docetaxel through SPRY2 downstream ERK signaling pathway; CASC2 and SPRY2 might be novel adjuvants for docetaxel-based chemotherapy for PC. Docetaxel 151-160 mitogen-activated protein kinase 1 Homo sapiens 186-189 29373811-7 2019 In summary, CASC2 competes with SPRY2 for miR-183 binding to rescue the expression of SPRY2 in PC cells, thus enhancing the sensitivity of PC cells to docetaxel through SPRY2 downstream ERK signaling pathway; CASC2 and SPRY2 might be novel adjuvants for docetaxel-based chemotherapy for PC. Docetaxel 254-263 mitogen-activated protein kinase 1 Homo sapiens 186-189 29589394-0 2018 Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. Docetaxel 34-43 mitogen-activated protein kinase 1 Homo sapiens 124-127 29589394-11 2018 CONCLUSION: The combination of baicalein and docetaxel effectively induced apoptosis and inhibited metastasis in 8505c cells through downregulation of apoptotic and angiogenic protein expression and blocking of the ERK and Akt/mTOR pathways in 8505c cells. Docetaxel 45-54 mitogen-activated protein kinase 1 Homo sapiens 215-218 25310895-8 2014 This study first reported the involvement of miR-451/c-Myc/ERK/GSK-3beta signalling axis in the acquisition of EMT phenotype in docetaxel-resistant LAD cells, suggesting that re-expression of miR-451 or targeting c-Myc will be a potential strategy for the treatment of chemoresistant LAD patients. Docetaxel 128-137 mitogen-activated protein kinase 1 Homo sapiens 59-62 25576381-5 2015 Significantly, C6 ceramide plus docetaxel caused dramatic human epidermal growth factor receptor (HER)-1/-2 degradation and downstream Akt/Erk inhibition in HER-2 expressing MDA-231 cells. Docetaxel 32-41 mitogen-activated protein kinase 1 Homo sapiens 139-142 23493035-0 2012 Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Docetaxel 167-176 mitogen-activated protein kinase 1 Homo sapiens 24-72 23566222-8 2013 Interrupting Vav3 signaling using siRNA enhanced docetaxel-induced cell growth suppression compared with that induced by docetaxel alone by inhibition of Akt and ERK phosphorylation, resulting in AR phosphorylation inhibition. Docetaxel 49-58 mitogen-activated protein kinase 1 Homo sapiens 162-165 23566222-8 2013 Interrupting Vav3 signaling using siRNA enhanced docetaxel-induced cell growth suppression compared with that induced by docetaxel alone by inhibition of Akt and ERK phosphorylation, resulting in AR phosphorylation inhibition. Docetaxel 121-130 mitogen-activated protein kinase 1 Homo sapiens 162-165 21995500-1 2012 AIMS: The aim of this work was to study if a G1-polyamidoamine dendrimer/siRNA dendriplex can remove the p42 MAPK protein in prostate cancer cells and to potentiate the anti-tumoral effect of the antidiabetic drug metformin and taxane docetaxel. Docetaxel 235-244 mitogen-activated protein kinase 1 Homo sapiens 105-113 23493035-0 2012 Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Docetaxel 167-176 mitogen-activated protein kinase 1 Homo sapiens 85-88 21798065-0 2011 Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK. Docetaxel 27-36 mitogen-activated protein kinase 1 Homo sapiens 95-98 20664934-0 2010 Role of extracellular signal-regulated kinase (ERK)1/2 in multicellular resistance to docetaxel in MCF-7 cells. Docetaxel 86-95 mitogen-activated protein kinase 1 Homo sapiens 8-54 17317842-0 2007 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Docetaxel 0-9 mitogen-activated protein kinase 1 Homo sapiens 155-196 14506750-0 2003 ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Docetaxel 31-40 mitogen-activated protein kinase 1 Homo sapiens 0-3 17951407-0 2007 Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Our previous studies showed that docetaxel-induced apoptosis of human melanoma cells was dependent on the activation of the c-jun NH(2)-terminal kinase (JNK) signaling pathway but was inhibited by the extracellular signal-regulated kinase (ERK)-1/2 pathway. Docetaxel 14-23 mitogen-activated protein kinase 1 Homo sapiens 310-357 17951407-0 2007 Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Our previous studies showed that docetaxel-induced apoptosis of human melanoma cells was dependent on the activation of the c-jun NH(2)-terminal kinase (JNK) signaling pathway but was inhibited by the extracellular signal-regulated kinase (ERK)-1/2 pathway. Docetaxel 142-151 mitogen-activated protein kinase 1 Homo sapiens 310-357 14506750-5 2003 We analyzed the effect of ERK inhibitors PD98059 and U0126 on vinorelbine- and docetaxel-induced cell growth suppression of androgen-independent prostate cancer cells. Docetaxel 79-88 mitogen-activated protein kinase 1 Homo sapiens 26-29 14688475-0 2003 Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway. Docetaxel 0-9 mitogen-activated protein kinase 1 Homo sapiens 64-67 34268250-0 2021 Quercetin Synergistically Enhances the Anticancer Efficacy of Docetaxel through Induction of Apoptosis and Modulation of PI3K/AKT, MAPK/ERK, and JAK/STAT3 Signaling Pathways in MDA-MB-231 Breast Cancer Cell Line. Docetaxel 62-71 mitogen-activated protein kinase 1 Homo sapiens 136-139